KU Leuven Center for Human Genetics and Leuven research Institute for Neuroscience and Disease (LIND), Leuven, Belgium ; VIB Center for the Biology of Disease, Leuven, Belgium.
PLoS One. 2014 Jan 21;9(1):e87014. doi: 10.1371/journal.pone.0087014. eCollection 2014.
Proteolytic processing of the amyloid precursor protein (APP) by the β- and γ-secretases releases the amyloid-β peptide (Aβ), which deposits in senile plaques and contributes to the etiology of Alzheimer's disease (AD). The α-secretase cleaves APP in the Aβ peptide sequence to generate soluble APPα (sAPPα). Upregulation of α-secretase activity through the 5-hydroxytryptamine 4 (5-HT4) receptor has been shown to reduce Aβ production, amyloid plaque load and to improve cognitive impairment in transgenic mouse models of AD. Consequently, activation of 5-HT4 receptors following agonist stimulation is considered to be a therapeutic strategy for AD treatment; however, the signaling cascade involved in 5-HT4 receptor-stimulated proteolysis of APP remains to be determined. Here we used chemical and siRNA inhibition to identify the proteins which mediate 5-HT4d receptor-stimulated α-secretase activity in the SH-SY5Y human neuronal cell line. We show that G protein and Src dependent activation of phospholipase C are required for α-secretase activity, while, unexpectedly, adenylyl cyclase and cAMP are not involved. Further elucidation of the signaling pathway indicates that inositol triphosphate phosphorylation and casein kinase 2 activation is also a prerequisite for α-secretase activity. Our findings provide a novel route to explore the treatment of AD through 5-HT4 receptor-induced α-secretase activation.
淀粉样前体蛋白(APP)的蛋白水解加工由β-和γ-分泌酶完成,释放出淀粉样β肽(Aβ),后者沉积在老年斑中,导致阿尔茨海默病(AD)的发病机制。α-分泌酶在 Aβ 肽序列中切割 APP,产生可溶性 APPα(sAPPα)。通过 5-羟色胺 4(5-HT4)受体上调α-分泌酶活性已被证明可以减少 Aβ 产生、淀粉样斑块负荷,并改善 AD 转基因小鼠模型的认知障碍。因此,激动剂刺激后 5-HT4 受体的激活被认为是 AD 治疗的一种治疗策略;然而,5-HT4 受体刺激 APP 蛋白水解涉及的信号级联仍有待确定。在这里,我们使用化学和 siRNA 抑制来鉴定介导 SH-SY5Y 人神经元细胞系中 5-HT4d 受体刺激的α-分泌酶活性的蛋白质。我们表明 G 蛋白和Src 依赖性激活磷脂酶 C 是α-分泌酶活性所必需的,而出乎意料的是,腺苷酸环化酶和 cAMP 不参与。对信号通路的进一步阐明表明,三磷酸肌醇磷酸化和酪蛋白激酶 2 激活也是α-分泌酶活性的前提条件。我们的研究结果为通过 5-HT4 受体诱导的α-分泌酶激活来探索 AD 的治疗方法提供了一条新途径。